Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

SAGE Therapeutics Company Profile (NASDAQ:SAGE)

Consensus Ratings for SAGE Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $52.35 (20.49% upside)

Analysts' Ratings History for SAGE Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetDetailsShare
2/27/2015Canaccord GenuitySet Price TargetBuy$58.00ViewTweet This Rating  Share This Rating on StockTwits
2/27/2015Canaccord GenuityReiterated RatingBuy$58.00ViewTweet This Rating  Share This Rating on StockTwits
2/24/2015Vetr Inc.UpgradeSell -> Hold$46.12ViewTweet This Rating  Share This Rating on StockTwits
2/23/2015Vetr Inc.DowngradeHold -> Sell$46.00ViewTweet This Rating  Share This Rating on StockTwits
1/27/2015SunTrustInitiated CoverageBuy$67.00ViewTweet This Rating  Share This Rating on StockTwits
1/13/2015Canaccord GenuityReiterated RatingBuy$58.00ViewTweet This Rating  Share This Rating on StockTwits
1/9/2015JPMorgan Chase & Co.Reiterated RatingOverweight$51.00ViewTweet This Rating  Share This Rating on StockTwits
12/9/2014Leerink SwannBoost Price TargetOutperform$46.00 -> $54.00ViewTweet This Rating  Share This Rating on StockTwits
9/24/2014Goldman SachsUpgradeNeutral -> Buy$29.56 -> $38.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2014Canaccord GenuityInitiated CoverageBuy$40.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2014JPMorgan Chase & Co.Initiated CoverageOverweight$42.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2014Goldman SachsInitiated CoverageNeutral$38.00ViewTweet This Rating  Share This Rating on StockTwits
8/12/2014Leerink SwannInitiated CoverageOutperform$46.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 3/1/2013 forward)